Sartorius to Acquire Albumedix for £415 Million

Sartorius announced that it has agreed to purchase Alubmedix through its French-listed subgroup Sartorius Stedim Biotech for £415 million (US$429 million) on Aug. 8, 2022. Albumedix is a provider of recombinant human albumin, which is used in various applications in the biopharmaceutical industry, such as an animal-free additive to cell culture media and for the stabilization of vaccines and viral therapies. The purchase is expected to close before the end of the third quarter of 2022.

According to a company press release, Albumedix will join Sartorius' Bioprocess Solutions Division. Its existing 72,000-ft2 site in Nottingham, UK, will be established as a center of excellence for innovation and good manufacturing practice-compliant production of raw materials.

“Albumedix will be an important addition to Sartorius’ advanced therapy solutions, particularly regarding our cell culture media business, as it will enable us to strengthen our position as a relevant supplier of innovative chemically defined media and critical ancillary materials,” said René Fáber, member of the executive board for the Bioprocess Solutions Division of Sartorius, in the press release. “This market offers high growth potential due to the increasing regulatory requirements as well as rising demand for the use of recombinant human albumin in near-patient applications. Albumedix will also add important formulation excipients to our vaccine production solutions, allowing us to expand our existing customer relationships and forge new ones.”

“We are delighted to be joining forces with Sartorius and look forward to accelerating our ambitious growth plans in delivering critical solutions to our global customers,” said Jonas S. Møller, CEO of Albumedix, in the release. “We have been highly impressed with Sartorius’ knowledge and capabilities in the bioprocessing markets, and we are excited to join this purposeful journey. We believe Sartorius will bring tremendous value in strengthening our market reach and broadening our innovation capacity, as well as significantly scaling up our existing platform.”

Source: Sartorius